Advanced or Recurrent Solid Tumors Treated With SHetA2

Phase 1 Recruiting 50 enrolled University of Oklahoma National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.

Timeline

Start: 2022-07-27
Primary completion: 2026-05
Completion: 2027-06

Publications

Mortan LF, Isingizwe ZR, Benbrook DM. Identification and Experimental Validation of Triosephosphate Isomerase 1 as a Functional Biomarker of SHetA2 Sensitivity in Ovarian Cancer. Cells. 2026 Jan 30;15(3):267. doi: 10.3390/cells15030267.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHetA2	Small molecule	5.4 mg/kg	Oral
Subject	SHetA2	Small molecule	7 mg/kg	Oral
Subject	SHetA2	Small molecule	9 mg/kg	Oral
Subject	SHetA2	Small molecule	12 mg/kg	Oral

Advanced or Recurrent Solid Tumors Treated With SHetA2

Summary

Timeline

Publications

Drugs

Indications